PI
LFCR icon

PEAK6 Investments’s Lifecore Biomedical LFCR Stock Holding History

PEAK6 Investments’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,524
Closed -$179K – 4344
2023
Q2 		$179K Buy
+18,524
New +$113K ﹤0.01% 2943
2022
Q3 		– Sell
-18,524
Closed -$179K – 5586
2022
Q2 		$179K Buy
+18,524
New +$183K ﹤0.01% 4850

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

PEAK6 Investments's LFCR Position: Q3 2023 in Review

PEAK6 Investments sold out of Lifecore Biomedical (LFCR) in Q3 2023, closing a stake of 18,524 shares — an estimated $179K sold.

PEAK6 Investments first reported a position in LFCR in Q2 2022 and held it in 2 quarters. The position peaked at $179K in Q2 2023. 69 funds tracked by Wall St. Rank hold LFCR as of Q3 2023.

  • PEAK6 Investments reported no remaining Lifecore Biomedical position as of Q3 2023 after selling out during the quarter.
  • PEAK6 Investments sold 18,524 Lifecore Biomedical shares in Q3 2023, an estimated $179K.
  • PEAK6 Investments first reported a position in Lifecore Biomedical in Q2 2022 and held it in 2 quarters.
  • PEAK6 Investments's Lifecore Biomedical position peaked at $179K in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.